image: Bruker's Biotyper enables molecular identification and taxonomical classification of bacteria, yeasts and fungi reliably and quickly using proteomic fingerprinting by high-throughput MALDI-TOF mass spectrometry. It covers more than 4,600 microbial isolates, including gram-negative bacteria, gram-positive bacteria, yeasts, multi-cellular fungi and mycobacteria. Microbial identification with the MALDI Biotyper allows for instantaneous identification of colonies from a plate. The system requires minimal sample preparation and has low consumables cost. The MALDI Biotyper is currently available in the US for research use only. view more
Credit: Bruker Corporation
Denver, Colorado – May 15, 2013 – A co-author of a groundbreaking study documenting reductions in patient length of stay and overall costs from implementation of an antibiotic stewardship program using Bruker's MALDI Biotyper will share her observations at a Bruker symposium to be held during the upcoming American Society for Microbiology (ASM) General Meeting. The study, which is currently available in an online edition1, showed that the average length of stay was reduced by two days for participants in the antibiotic stewardship intervention group and overall costs were reduced by almost $20,000 per patient.
"We know that time is the enemy when dealing with serious infections," noted George Goedesky, Executive Director of Marketing/ Business Development. "This study demonstrates that reducing the time to diagnosis and optimal treatment through use of a rapid and accurate pathogen identification system, such as the MALDI Biotyper, when integrated into a comprehensive antibiotic stewardship program, improves patient care while significantly reducing length of stay and total costs."
The authors from The Methodist Hospital in Houston Texas set out to assess how patient care could be improved and cost savings achieved by a combination of rapid pathogen identification and a systematic approach to antimicrobial stewardship. Study patients with gram-negative blood infections were assigned to either routine care or to the intervention program, which included rapid pathogen identification and immediate antimicrobial susceptibility testing using the MALDI Biotyper, along with protocols for timely communication of results to inform therapeutic decisions.
The study authors report that in the pre-intervention period, final pathogen identification and susceptibility results took on average 47.1 hours, and in the intervention period, final results took 24.4 hours on average. The mean time to organism identification was 36.6 hours in the pre¬-intervention group versus 10.2 hours in the intervention arm. The mean length of stay in the pre-intervention group was 11.9 days with a mean hospital cost of $45,709. In the intervention group, length of stay averaged 9.3 days at an average cost of $26,162.
Patricia Cernoch, Manager of the Microbiology Laboratory at Methodist Hospital and a study co-author, commented, "At a time when pressures to reduce costs while improving patient care are escalating, we are delighted to show that combining a rapid and accurate pathogen detection system such as the MALDI Biotyper with common sense improvements in communication and treatment protocols produced such positive results for both patients and the hospital. We look forward to helping to implement similar programs throughout our system."
The MALDI Biotyper is the market-leading system for microbial identification based on MALDI-TOF mass spectrometry. It is widely used in clinical microbiology, industrial microbiology, animal health and food safety and has become the laboratory standard for next generation microbial identification. The Biotyper system covers a broad range of more than 4,600 microbial isolates from gram-negative bacteria, gram-positive bacteria, yeasts, multi-cellular fungi and mycobacteria. Microbial identification with the MALDI Biotyper uses a proteomic fingerprint and allows for instantaneous identification of colonies from a plate. This unique species-specific pattern is automatically compared with reference spectra in the MALDI Biotyper library. In addition, the MALDI Biotyper supports the Open Microbiology Concept which allows customers to generate their own database entries from regional isolates.
The Bruker MALDI Biotyper is currently available for research use in the U.S. FDA clearance for clinical use is expected later this year.
1. Arch Pathol Lab Med. doi: 10.5858/arpa.2012-0651- OA. Published Online December 6, 2012.
Visit Bruker's ASM booth #715 to learn more about the MALDI Biotyper. The 113th General Meeting of the American Society for Microbiology will be held in Denver, Colorado May 18- 21, 2013. For more information, visit http://gm.asm.org/
About the Bruker MALDI Biotyper
The dedicated MALDI Biotyper solution enables molecular identification, and taxonomical classification or de-replication of microorganisms like bacteria, yeasts and fungi. Classification and identification of microorganisms is achieved reliably and quickly using proteomic fingerprinting by high-throughput MALDI-TOF mass spectrometry. Applications include clinical routine microbial identification, environmental and pharmaceutical analysis, taxonomical research, food and consumer product safety and quality control, as well as marine microbiology. The robust MALDI Biotyper method requires minimal sample preparation and offers low consumables cost. The MALDI Biotyper is available in a research-use-only version, or in an IVD-CE version according to EU directive EC/98/79 in various European countries. In the United States, the MALDI Biotyper is available for research use only, and not for use in diagnostic procedures. About Bruker Corporation
Bruker Corporation is a leading provider of high-performance scientific instruments and solutions for molecular and materials research, as well as for industrial and applied analysis. For more information, please visit http://www.bruker.com.
Journal
Archives of Pathology & Laboratory Medicine